Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CLDN18.2 heavy chain antibody Fc fusion protein DR30303

A fusion protein composed of a recombinant humanized anti-Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) heavy chain antibody (VHH) fused to an engineered immunoglobulin gamma-1 (IgG1) Fc fragment, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CLDN18.2 heavy chain antibody Fc fusion protein DR30303 specifically targets, binds to and inhibits CLDN18.2 expressed on tumor cells. The binding induces antibody-dependent cellular cytotoxicity (ADCC) and may kill CLDN18.2-expressing tumor cells and inhibit tumor cell proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is overexpressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CLDN18.2 VHH-Fc DR30303
fusion protein DR30303
VHH-Fc DR30303
Code name:DR 30303
DR-30303
DR30303
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search